New perspectives on targeted therapy in ovarian cancer

Coward, J. I. G., Middleton, K. and Murphy, F. (2015) New perspectives on targeted therapy in ovarian cancer. International Journal of Women's Health, 7 189-203. doi:10.2147/IJWH.S52379

Author Coward, J. I. G.
Middleton, K.
Murphy, F.
Title New perspectives on targeted therapy in ovarian cancer
Journal name International Journal of Women's Health   Check publisher's open access policy
ISSN 1179-1411
Publication date 2015-02-04
Year available 2015
Sub-type Article (original research)
DOI 10.2147/IJWH.S52379
Open Access Status DOI
Volume 7
Start page 189
End page 203
Total pages 5502
Place of publication Macclesfield, United Kingdom
Publisher Dove Medical Press
Language eng
Subject 2730 Oncology
2729 Obstetrics and Gynaecology
2913 Maternity and Midwifery
Abstract Epithelial ovarian cancer remains the most lethal gynecologic malignancy. During the last 15 years, there has been only marginal improvement in 5 year overall survival. These daunting statistics are compounded by the fact that despite all subtypes exhibiting striking heterogeneity, their systemic management remains identical. Although changes to the scheduling and administration of chemotherapy have improved outcomes to a degree, a therapeutic ceiling is being reached with this approach, resulting in a number of trials investigating the efficacy of targeted therapies alongside standard treatment algorithms. Furthermore, there is an urge to develop subtype-specific studies in an attempt to improve outcomes, which currently remain poor. This review summarizes the key studies with antiangiogenic agents, poly(adenosine diphosphate [ADP]-ribose) inhibitors, and epidermal growth factor receptor/human epidermal growth factor receptor family targeting, in addition to folate receptor antagonists and insulin growth factor receptor inhibitors. The efficacy of treatment paradigms used in non-ovarian malignancies for type I tumors is also highlighted, in addition to recent advances in appropriate patient stratification for targeted therapies in epithelial ovarian cancer.
Keyword Antiangiogenic therapy
High-grade serous
Low grade ovarian cancer
PARP inhibition
Cancer-related inflammation
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: Mater Research Institute-UQ (MRI-UQ)
Official 2016 Collection
School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 38 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 43 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 17 Feb 2015, 10:19:01 EST by System User on behalf of Mater Research Institute-UQ